We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KLAC:NASDAQKLA Corporation Analysis

Data as of 2026-09-07 - not real-time

$185.60

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind KLA Corporation is neutral at $185.60, with no clear ordering between short and long averages. Over a rolling month the price has lost 11.8%. Relative strength is 47.4 — neutral — and the MACD signal is bullish. The recent range runs from support at $167.05 up to resistance at $214.80.
Valuation screens as overvalued: a P/E of 50.7 sits above the sector average of 33.2. Consensus targets land 26.0% above where the shares trade now. Revenue is growing at 15.2% on a 35.6% profit margin. The 0.50% dividend yield looks covered by current payout levels.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 61.9%, a beta of 2.81 and a maximum drawdown of 43.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.

Top Market Events

KLA Corporation recently declared a quarterly cash dividend of US$0.Semiconductor manufacturing equipment maker KLA Corporation NASDAQ:KLAC reported Q2 CY2026 results , with sales up 15.KLA Corp KLAC achieves record revenue of $3.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Trading above the 200-day average of 171.52
  • MACD momentum is positive
  • 30-day price change of -11.8%

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 50.7 versus sector average of 33.2
  • Trading above the 200-day average of 171.52
  • Analyst targets imply +26.0% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 50.7 versus sector average of 33.2
  • Analyst targets imply +26.0% versus the current price
  • Profit margin of 35.6% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth15.20%
Profit Margin35.57%
P/E Ratio50.7
ROE87.50%
ROA20.80%
Debt/Equity96.88
P/B Ratio38.2
Op. Cash Flow$4.1B
Free Cash Flow$2.6B
Industry P/E33.2

Technical Analysis

TrendNeutral
RSI47.4
Support$167.05
Resistance$214.80
MA 20$187.87
MA 50$205.76
MA 200$171.52
MACDBullish
VolumeDecreasing
Fear & Greed Index94.11

Valuation

Fair Value$46.74
Target Price$233.77
Upside/Downside25.95%
GradeOvervalued
TypeGrowth
Dividend Yield0.50%

Risk Assessment

Beta2.81
Volatility61.94%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.